National Bank of Canada’s Anavex Life Sciences AVXL Stock Holding History

National Bank of Canada’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.53K	Sell	5 -3,037	-100%	-$13.2K	﹤0.01%	2639
2025 Q4	$1.08M	Sell	3,042 -880	-22%	-$5.39K	﹤0.01%	1184
2025 Q3	$3.49M	Sell	3,922 -173	-4%	-$1.75K	﹤0.01%	960
2025 Q2	$3.78M	Buy	4,095 +1,354	+49%	+$11.6K	﹤0.01%	1007
2025 Q1	$2.35M	Buy	+2,741	New	+$25.9K	﹤0.01%	1029
2024 Q3	–	Sell	-225	Closed	-$92.5K	–	2764
2024 Q2	$92.5K	Hold	225	–	–	﹤0.01%	1508
2024 Q1	$85.7K	Buy	+225	New	+$1.27K	﹤0.01%	1592

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

National Bank of Canada's AVXL Position: Q1 2026 in Review

National Bank of Canada reduced its Anavex Life Sciences (AVXL) stake by 100% in Q1 2026, selling an estimated $1.32M and leaving 1,500 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2476.

National Bank of Canada first reported a position in AVXL in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.5M in Q3 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

National Bank of Canada held 1,500 shares of Anavex Life Sciences worth $4.59K as of Q1 2026.
National Bank of Canada sold 303,700 Anavex Life Sciences shares in Q1 2026, an estimated $1.32M.
Anavex Life Sciences made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2476 holding.
National Bank of Canada first reported a position in Anavex Life Sciences in Q4 2021 and has held it in 18 quarters since.
National Bank of Canada's Anavex Life Sciences position peaked at $3.5M in Q3 2025.
190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.